KR102011826B1

KR102011826B1 - Skin external composition interleukin 13

Info

Publication number: KR102011826B1
Application number: KR1020120148356A
Authority: KR
Inventors: 한지연; 이은경; 조은경; 이태룡
Original assignee: (주)아모레퍼시픽
Priority date: 2012-12-18
Filing date: 2012-12-18
Publication date: 2019-08-19
Also published as: KR20140078973A

Abstract

The present invention relates to a skin whitening composition containing interleukin 13 (IL-13), and more particularly, to contain the IL-13 to inhibit pigmentation and differentiation of adult melanocytes in the skin, thereby providing a skin whitening effect. The present invention relates to an external preparation composition for skin, which is effective for the treatment of hyperpigmented skin diseases such as blemishes or surpluses.

Description

Skin external composition comprising interleukin 13 {Skin external composition interleukin 13}

The present invention relates to a skin whitening composition containing interleukin 13 (IL-13), and more particularly, to contain the IL-13 to inhibit pigmentation and differentiation of adult melanocytes in the skin, thereby providing a skin whitening effect. The present invention relates to an external composition for skin, which is effective for the treatment of hyperpigmented skin diseases such as blemishes or surpluses.

Adult melanocytes exist in the basal epidermis of the skin epidermis, and act to inhibit the DNA damage of the keratinocytes by transferring the melanin pigment produced by the production of melanin pigment by external factors such as UV to the surrounding keratinocytes. do. However, the activity of these adult melanocytes is abnormally regulated according to genetic factors, hormones, and various disease factors, and it is a factor that causes hyperpigmentation diseases such as blemishes or surpluses due to excessive pigment production and hyperplasia beyond the normal pigment production stage.

The disease is known to be caused by abnormal activity of melanocytes located in the dermis, and the pigments thus produced are not normally removed by keratinocyte dropouts, causing cosmetic problems. In order to control the hyperpigmented disease, various regulatory factors derived from the cells constituting the skin have been studied. However, the effect of IL-13, a skin immune cell-derived factor, directly on adult melanocytes is not well known. . To date, IL-13 has been studied as a factor inducing the maturation of immune cells. Specifically, IL-13 has been studied mainly as an asthma-inducing factor that causes hyperproliferation of respiratory fibroblasts, and also as a major immune factor that causes psoriasis, which is caused by abnormal proliferation of keratinocytes in the skin. The effect of IL-13 directly on adult melanocytes has not been studied.

The present inventors have found that IL-13 affects the pigmentation and cell proliferation of adult melanocytes, thereby finding that IL-13 can be utilized to inhibit the pigmentation of skin melanin cells, thereby completing the present invention. It became.

It is therefore an object of the present invention to provide a composition containing IL-13 which inhibits adult melanocyte activity in the skin.

In order to achieve the above object, the present invention provides an external composition for skin whitening containing IL-13.

The composition according to the present invention can provide skin whitening effect by inhibiting the activation of melanocytes in the skin by containing IL-13, in addition to alleviating and treating the symptoms of hyperpigmented skin diseases such as blemishes or surpluses. effective.

Figure 1 is a graph showing the result of reduced gene expression of melanin production-related factors in human melanocytes treated with IL-13.
Figure 2 is a visual representation of the change in the enzyme activity of tyrosinase through the change in the amount of melanin pigment formation in human melanocytes treated with IL-13.
3 is a graph showing the results of inhibition of cell proliferation in human melanocytes treated with IL-13.

The present invention relates to an external preparation composition for skin that can provide a skin whitening effect by inhibiting activation of adult melanocytes, preventing the production of melanin pigment, and inhibiting the differentiation of adult melanocytes. IL-13) as an active ingredient.

IL-13 for use in the present invention can be obtained from a number of suitable sources (eg, human recombinant IL-13, R & D systems, product no. 213-IL). This can be produced by recombinant DNA methodology, for example, in which genes encoding human IL-13 are cloned and expressed in a host system while allowing the production of large amounts of pure human IL-13. Biologically active structural units or fragments of IL-13 can also be used in the present invention.

The composition of the present invention contains IL-13 used as an active ingredient in an amount of 0.0001 to 0.0005% by weight based on the total weight of the composition. Or less than 0.0001% by weight of their pharmaceutically acceptable salts is not sufficient to inhibit the activity of tyrosinase for whitening of the skin, and more than 0.0005% by weight of the salt is suitable for the content and formulation of other ingredients. I can't.

The composition according to the invention provides an excellent skin lightening effect and is also effective in alleviating and treating the symptoms of hyperpigmented skin diseases such as blemishes or surpluses.

The composition according to the present invention may be formulated into a topical external preparation, a conventional external preparation, a cosmetic formulation or a pharmaceutical formulation.

The composition according to the invention may be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example emulsions, suspensions, microemulsions, microcapsules, microgranules or ionic (liposomes) and non-obtained by dispersing an oil phase in solution, gels, solids, pasty anhydrous products, aqueous phases. It may be provided in the form of an ionic vesicle dispersant or in the form of a cream, skin, lotion, powder, ointment, spray or cone stick. It may also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions can be prepared according to conventional methods in the art.

In addition, the composition according to the present invention is a fatty substance, an organic solvent, a dissolving agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, water, an ionic or nonionic. Such as type emulsifiers, fillers, metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredients commonly used in cosmetics. It may contain adjuvants conventionally used in the cosmetic or dermatology field. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological arts.

In addition, the compositions according to the invention may be formulated as pharmaceutical compositions further containing appropriate pharmaceutically acceptable carriers, excipients and diluents.

The pharmaceutical dosage form of the present invention is not particularly limited, but may be used alone or in combination with other pharmaceutically active compounds.

The pharmaceutical compositions according to the invention can be used in any form suitable for pharmaceutical preparations, including transdermal formulations such as lotions, ointments, gels, creams, patches, sprays, respectively, according to conventional methods.

Preferred dosages of the pharmaceutical compositions of the present invention vary depending on the subject's age, sex, weight, symptoms, extent of disease, drug form, route of administration and duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the pharmaceutical composition of the present invention may be administered in the range of 0.05 mg / kg / day to 2500 mg / kg / day, but is not limited thereto. Administration may be once a day or may be divided several times. In addition, the dosage may be increased or decreased depending on age, sex, weight, degree of disease, route of administration, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin lightening effect.

Hereinafter, the content of the present invention will be described in more detail through examples and test examples. These examples are provided only for understanding the contents of the present invention, but the scope of the present invention is not limited to these examples and test examples, and modifications, substitutions, and insertions commonly known in the art may be performed. It may be included in the scope of the present invention.

[ Reference Example 1] Preparation of melanocytes

Normal human Epidermal Melanocyte-Darkelyy pigmented (C-102-5C), purchased from Cascade, was planted in 100 x 2 plates in 2 x 10 ⁵ counts, and the basal medium was HMGS (Human Melanocyte Growth Supplement, 254 medium containing S-002-5, Gibco) (product number M-254-500, Gibco) was used and incubated in a 37 ° C., 5% CO ₂ incubator. Passage was cultured when the density was about 70% to 80%, and the melanocytes that were passaged were provided to subsequent experiments.

[ Test Example One] IL Decreased Expression of Melanin-related Factors in Melanocytes by -13

Human melanocytes were treated with IL-13 to determine whether the pigment production of melanocytes was reduced by IL-13. IL-13 used IL-13 (product number 213-IL) purchased from R & D systems.

Human melanocytes cultured in Reference Example 1 were incubated for 72 hours in a basic medium (254 medium, product number M-254-500; Gibco) containing HMGS at 37 ℃, 5% CO ₂ incubator. The cultured human melanocytes were incubated for 72 hours under the above conditions using melanocytes treated with IL-13 at a concentration of 2, 10, 50 ng / ml and nothing as a control. Total mRNA of the cultured human melanocytes was extracted and the relative expression difference of tyrosinase-related protein 2 (TRP2) gene, a melanin-producing enzyme, was measured between samples using real-time PCR. At this time, the primer is a primer for human TRP2 (human dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2), Applied Biosystems, product number; Hs01098278_m1 *) was used, and a total of 40 cycles of cycles of 15 seconds at 60 ° C. and 60 seconds at 60 ° C. were repeated 40 times to determine the relative value of the expression of the gene. The measurement result is shown in FIG.

Through the results shown in FIG. 1, the expression amount of TRP2, a pigment-producing enzyme, was reduced depending on the concentration of IL-13, and in particular, when IL-13 was treated at a concentration of 10 ng / ml or more, It can be seen that it can be reduced to more than 60%.

[ Test Example 2] IL Tyrosinase, an enzyme related to melanogenesis of melanocytes by -13 tyrosinase ) Change in activity

After treating the sample under the same conditions as in Test Example 1, the cells were incubated for 72 hours at 37 ° C. in a 5% CO ₂ incubator to centrifuge the cell lysate (eppendorf, centrifuge 5415R, Germany), and the pellets were separated to visualize color. Observed by. The results are shown in FIG.

2, the amount of melanin pigment formation was reduced depending on the concentration of IL-13 by treatment with IL-13. In particular, the amount of pigment formation was markedly decreased when IL-13 was treated at a concentration of 10 ng / ml or more. You can check it. Through this, it can be seen that the enzyme activity of tyrosinase can be significantly reduced by the treatment of IL-13.

[ Test Example 3] IL -13 Reduces Cell Proliferation of Pigment-Producing Cells

In order to confirm the effect of IL-13 of the present invention on the reduction of cell proliferation of pigment-producing cells, melanocytes cultured in Reference Example 1 were planted at 3 X 10 ² in a 96-well plate, and IL -13 was treated at various concentrations (1, 5, 10, 50, 100 ng / ml) and then incubated for 72 hours in a 37 ° C., 5% CO ₂ incubator. At this time, in order to observe the proliferation difference by time, the experiment was divided into three groups so as to check every 24 hours, 48 hours and 72 hours, under the above conditions using melanin cells that did not process anything as a control group of each group Incubated for each hour. After treatment with IL-13 by concentration, the cell sample was measured using a BrdU kit (cell proliferation ELISA, BrdU (colormetric), product number; 11296736001, Roche) purchased from Roche applied science. . The measurement results are shown in FIG. 3.

Through the results shown in Figure 3, the treatment of melanocytes with IL-13 reduced the proliferation of pigment-producing cells, especially after 72 hours it can be seen that significantly reduced proliferation of pigment-producing cells.

Claims

A whitening cosmetic composition containing IL-13 as an active ingredient in an amount of 0.0001 to 0.0005% by weight based on the total weight of the composition.

delete

The cosmetic composition according to claim 1, wherein the composition inhibits pigmentation or cell proliferation of adult melanocytes.

The cosmetic composition according to claim 1, wherein the composition improves hyperpigmented skin disease.

The cosmetic composition according to claim 4, wherein the hyperpigmented skin disease is a blemish or surplus.

A pharmaceutical composition for improving hyperpigmented skin disease, comprising IL-13 as an active ingredient in an amount of 0.0001 to 0.0005% by weight based on the total weight of the composition.

The pharmaceutical composition of claim 6, wherein the hyperpigmented skin disease is a blemish or surplus.